Rtgn.Pk

RTGN.PK exhibits a highly leveraged capital structure, with total liabilities of $23.24 million and total equity of -$2.30 million, resulting in a debt-to-equity ratio of -0.02. The company's liquidity position is weak, as evidenced by a current ratio of 0.01, indicating that it holds significantly more current liabilities than current assets. The negative net income of -$2.43 million and operating cash flow of -$558,350 further underscore the company's financial distress.

Profitability metrics are severely negative, with a return on assets (ROA) of -115.43%, indicating that the company is generating substantial losses relative to its asset base. The return on equity (ROE) of 1.05 is misleading due to the negative equity base, and does not reflect a strong return for shareholders. These figures are well below the industry median for ROA and ROE, which typically indicate a healthy return for biotechnology firms.

The company's revenue is reported as $0, suggesting it is not currently generating any income from operations. This lack of revenue is a critical concern, as it indicates the company is not monetizing its products or services effectively. The absence of revenue also implies that the company is relying entirely on external financing or asset sales to sustain operations.

Looking at the growth trajectory, the company is not showing any signs of revenue growth, as it is not generating any revenue. The negative operating income of -$2.42 million and net income of -$2.43 million indicate that the company is not only failing to grow but is also incurring significant losses. The outlook for the current fiscal year and the next fiscal year is likely to remain negative unless the company can achieve a significant turnaround in its operations.

The risk assessment highlights several critical issues. The company's liquidity risk is rated as medium, primarily due to its negative net cash position after accounting for total debt. The dilution risk is rated as low, but the company's negative equity and high debt levels suggest that it may need to issue additional shares to raise capital, which could dilute existing shareholders' ownership. The risk factors include the company's inability to generate revenue and its reliance on external financing.

Recent events and filings indicate that the company is facing significant financial challenges. The absence of revenue and the substantial losses suggest that the company may be in a liquidity crisis. The company's financial statements and disclosures do not provide any clear indication of a path to profitability or revenue generation, which raises concerns about its long-term viability.